Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenofovir amibufenamide vs entecavir in chronic hepatitis B (China, prospective multicenter cohort)
ChiCTR2400085341Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Jun 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of tenofovir + amibufenamide and entecavir in Chronic Hepatitis B (CHB) (2 arms), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoint: HBV-DNA negative conversion rate. Started Jun 2024; status: recruiting.
02
Drugs
tenofovir + amibufenamideentecavir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2400085341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400085341.